Pinsent Masons advises on Retroscreen AIM Listing

03 May 2012 | 10:22 am |

International law firm Pinsent Masons has advised Retroscreen, an antiviral clinical trials specialist, on its admission to the AIM market of the London Stock Exchange, raising £15m and with a market capitalisation of £32.8m.

Retroscreen is a virology healthcare business which provides clinical and pre-clinical analytical services for flu and cold antiviral products to global pharmaceutical and biotechnology organisations. As the business develops, it intends to expand into adjacent clinical areas, such as asthma.

 Kym Denny, CEO of Retroscreen, said: "I am delighted that Retroscreen has today joined AIM and I would like to welcome all our new shareholders to the Company. It is a very exciting day for Retroscreen, and one which we believe will be transformational for the development of the business.”

 The Pinsent Masons team advising on the deal was led by Corporate Partner Russell Booker, assisted by Corporate Senior Associate Iain Butler, Corporate Solicitor James Paton-Philip, Legal Director Louise Fullwood (Commercial), Employment Partner Michael Ryley and Tax Senior Associate Conor Brindley.

 Commenting on the deal, Russell said: "We are delighted to have assisted Retroscreen with the AIM listing, which will enable the business to expand its clinical and pre-clinical offering in the UK."

Latest press releases

Show me all press releases

Pinsent Masons advises NTR plc on 54MW portfolio of co-located solar and battery storage projects in Ireland

Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.

Pinsent Masons advises on Four Seasons Care Homes portfolio migration

Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.

Pinsent Masons advises Teva Pharmaceuticals on €84m sale of its consumer healthcare brand portfolio to Karo Pharma AB.

Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises NTR plc on 54MW portfolio of co-located solar and battery storage projects in Ireland

Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.

Pinsent Masons advises on Four Seasons Care Homes portfolio migration

Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts